You are here: Home » PTI Stories » National » News
Business Standard

Aurobindo gets USFDA nod for generic cough relief tablets

Press Trust of India  |  New Delhi 

Pharma today said it has received final approval from the US health regulator to manufacture the generic version of Reckitt Benckiser's Mucinex DM cough relief tablets.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg, Pharma said in a filing.



The tablets help loosen mucus and phlegm, and thin out bronchial secretions, making cough more productive, it added.

The product will be launched in the first quarter of 2017-18, it said.

Citing IRI data, Pharma said the tablets had an estimated market size of USD 235 million for the 12-months ended December 2016.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Aurobindo gets USFDA nod for generic cough relief tablets

Aurobindo Pharma today said it has received final approval from the US health regulator to manufacture the generic version of Reckitt Benckiser's Mucinex DM cough relief tablets. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg, Aurobindo Pharma said in a BSE filing. The tablets help loosen mucus and phlegm, and thin out bronchial secretions, making cough more productive, it added. The product will be launched in the first quarter of 2017-18, it said. Citing IRI data, Aurobindo Pharma said the tablets had an estimated market size of USD 235 million for the 12-months ended December 2016. Pharma today said it has received final approval from the US health regulator to manufacture the generic version of Reckitt Benckiser's Mucinex DM cough relief tablets.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg, Pharma said in a filing.

The tablets help loosen mucus and phlegm, and thin out bronchial secretions, making cough more productive, it added.

The product will be launched in the first quarter of 2017-18, it said.

Citing IRI data, Pharma said the tablets had an estimated market size of USD 235 million for the 12-months ended December 2016.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Aurobindo gets USFDA nod for generic cough relief tablets

Pharma today said it has received final approval from the US health regulator to manufacture the generic version of Reckitt Benckiser's Mucinex DM cough relief tablets.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg, Pharma said in a filing.

The tablets help loosen mucus and phlegm, and thin out bronchial secretions, making cough more productive, it added.

The product will be launched in the first quarter of 2017-18, it said.

Citing IRI data, Pharma said the tablets had an estimated market size of USD 235 million for the 12-months ended December 2016.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22